Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

Haloperidol

Catalog No.
B2099
An antipsychotic drug, commonly used to construct tardive dyskinesia animal models.
Grouped product items
Size Price Stock Qty
10mM (in 1mL DMSO)
$55.00
In stock
500mg
$73.00
In stock
1g
$137.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Haloperidol (CAS 52-86-8) is an antipsychotic drug with functions similar to those of phenothiazine antipsychotics[1].

Haloperidol is a dopamine inverse agonist. Haloperidol also inhibits neurological function, thereby relieving tension, and is a highly potent antipsychotic with a potency about 50 times that of chlorpromazine, equally effective against delusional and hallucinatory symptoms. These effects are mainly achieved by blocking dopamine receptors in the cerebral cortex and limbic system; blockade of dopamine receptors in the nigrostriatal pathway accounts for related side effects such as akathisia and dystonia[1].

Long-term administration of haloperidol induces movement disorders such as oral dyskinesia in rodents and is commonly used to establish tardive dyskinesia animal models.

References: [1] Dr Ananya Mandal, MD. Haloperidol Pharmacology.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt375.86
Cas No.52-86-8
FormulaC21H23ClFNO2
Solubilityinsoluble in H2O; ≥18.79 mg/mL in DMSO; ≥2.52 mg/mL in EtOH with gentle warming and ultrasonic
Chemical Name4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
Canonical SMILESOC1(CCN(CCCC(c(cc2)ccc2F)=O)CC1)c(cc1)ccc1Cl
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Animal experiment:[1]

Animal models

Male Sprague-Dawley rats, 225 ~ 250 g

Dosage form

0, 0.01, 0.05, 0.1 or 0.5 mg/kg

Administered subcutaneously

Applications

In rats, the dopamine agonist apomorphine (APO) caused a significant decrease in prepulse inhibition (PPI) of the acoustic startle response, which could be reversed in a dose-dependent manner by haloperidol. PPI of the acoustic startle response is a measure of sensorimotor gating that is impaired in both schizophrenic patients and in rats treated with dopamine agonists. The ability of antipsychotics such as haloperidol to restore PPI in APO-treated rats correlates significantly with their clinical potency.

Note

The technical data provided above is for reference only.

References:

1. Swerdlow NR, Geyer MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav. 1993 Mar;44(3):741-4.

Quality Control

User Guide